CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
Cyclosporine +1 moredrug
Likely dose
Cyclosporine 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00713193
NCT00713193Phase 3Completed
CompareCT.gov

A Multi-Center, Randomized Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in the Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)

Ohio State University·interventional·Posted Jul 11, 2008·Updated May 3, 2023

In Brief

A Phase 3 clinical trial evaluating Cyclosporine and Prednisone for Thrombotic Thrombocytopenic Purpura. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombotic Thrombocytopenic Purpura
CountriesUnited States
CollaboratorsFood and Drug Administration (FDA)

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2008
Enrollment StartNov 1, 2007
Primary CompletionSep 20, 2017
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 18.0 years ago

Interventions

Cyclosporinedrug

2-3 mg/kg orally in a twice day divided dose for 6 months

Prednisonedrug

1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.